Alcohol use disorder (AUD) is a brain disorder associated with high rates of mortality and morbidity worldwide. Baclofen, a selective gamma-aminobutyric acid-B (GABAB) receptor agonist, has emerged as a promising drug for AUD. The use of this drug remains controversial, in part due to uncertainty regarding dosing and efficacy, alongside concerns about safety. The maintenance dose varies widely from 30 to more than 300 mg/day. Baclofen may be particularly advantageous in those with liver disease, due to its limited hepatic metabolism and safe profile in this population. Patients should be...

En enero de 2017, Isaac Whitman y un grupo de investigadores reportaron que, en el estudio que hicieron con más de 14 millones de personas, el consumo problemático de alcohol es un factor de riesgo evitable para:

• infarto al miocardio
• falla cardiaca congestiva
• fibrilación auricular

Esta investigación aporta evidencia contra los supuestos “beneficios” del consumo de alcohol para la salud cardiovascular.

Pueden leer los detalles en: https://sin-adiccion.blogspot.com/2017/01/abuso-de-alcohol-y-enfermedades.html?q=alcohol

Nowadays there is some evidence available that points out that physical activity/exercise can be beneficial in the treatment of alcohol use disorders (AUD) and its comorbidities, like anxiety and depression. This beneficial effect is very important to consider, particularly because current treatment options of AUD are effective for some but not all patients and many experience relapses.

On August 28, 2017, Mats Hallgren and a group of researchers published the article “More Reasons to Move: Excercise in the Treatment of Alcohol Use Disorders”. After reviewing the available evidence from...